FILE PHOTO: The peak of Mount Pilatus is seen in the background as workers clean the windows of a building of Roche in Rotkreuz May 27, 2020. REUTERS/Arnd Wiegmann/File Photo
ZURICH (Reuters) – Roche Holding’s experimental drug etrolizumab did not fare well in late-stage clinical trials in treating people with moderate to severe ulcerative colitis, the Swiss drugmaker said bit.ly/33KLTqS on Monday.
“Mixed results were seen in studies evaluating etrolizumab as an induction therapy, and both studies evaluating etrolizumab as a maintenance therapy failed to meet their primary endpoints, showing no significant difference in the proportion of people achieving remission with subcutaneous etrolizumab versus placebo,” it said.
“We are disappointed with these results, because we know that people with ulcerative colitis need new treatment options,” said Levi Garraway, Roche’s chief medical officer and head of global product development. A phase III study of etrolizumab in Crohn’s disease continued.
Reporting by Michael Shields; editing by Thomas Seythal
vCard.red is a free platform for creating a mobile-friendly digital business cards. You can easily create a vCard and generate a QR code for it, allowing others to scan and save your contact details instantly.
The platform allows you to display contact information, social media links, services, and products all in one shareable link. Optional features include appointment scheduling, WhatsApp-based storefronts, media galleries, and custom design options.